Gao Weibo, Fan Jiasai, Sun Di, Yang Mengxi, Guo Wei, Tao Liyuan, Zheng Jingang, Zhu Jihong, Wang Tianbing, Ren Jingyi
Department of Emergency, Peking University People's Hospital, Beijing, China.
Department of Cardiology, Heart Failure Center, China-Japan Friendship Hospital, Beijing, China.
Front Cardiovasc Med. 2021 Nov 26;8:738814. doi: 10.3389/fcvm.2021.738814. eCollection 2021.
The relationship between cardiac functions and the fatal outcome of coronavirus disease 2019 (COVID-19) is still largely underestimated. We aim to explore the role of heart failure (HF) and NT-proBNP in the prognosis of critically ill patients with COVID-19 and construct an easy-to-use predictive model using machine learning. In this multicenter and prospective study, a total of 1,050 patients with clinical suspicion of COVID-19 were consecutively screened. Finally, 402 laboratory-confirmed critically ill patients with COVID-19 were enrolled. A "triple cut-point" strategy of NT-proBNP was applied to assess the probability of HF. The primary outcome was 30-day all-cause in-hospital death. Prognostic risk factors were analyzed using the least absolute shrinkage and selection operator (LASSO) and multivariate logistic regression, further formulating a nomogram to predict mortality. Within a 30-day follow-up, 27.4% of the 402 patients died. The mortality rate of patients with HF likely was significantly higher than that of the patient with gray zone and HF unlikely (40.8% vs. 25 and 16.5%, respectively, < 0.001). HF likely [Odds ratio (OR) 1.97, 95% CI 1.13-3.42], age (OR 1.04, 95% CI 1.02-1.06), lymphocyte (OR 0.36, 95% CI 0.19-0.68), albumin (OR 0.92, 95% CI 0.87-0.96), and total bilirubin (OR 1.02, 95% CI 1-1.04) were independently associated with the prognosis of critically ill patients with COVID-19. Moreover, a nomogram was developed by bootstrap validation, and C-index was 0.8 (95% CI 0.74-0.86). This study established a novel nomogram to predict the 30-day all-cause mortality of critically ill patients with COVID-19, highlighting the predominant role of the "triple cut-point" strategy of NT-proBNP, which could assist in risk stratification and improve clinical sequelae.
心脏功能与2019冠状病毒病(COVID-19)致死结局之间的关系仍在很大程度上被低估。我们旨在探讨心力衰竭(HF)和N末端B型利钠肽原(NT-proBNP)在COVID-19危重症患者预后中的作用,并使用机器学习构建一个易于使用的预测模型。在这项多中心前瞻性研究中,连续筛查了总共1050例临床怀疑患有COVID-19的患者。最终,纳入了402例实验室确诊的COVID-19危重症患者。应用NT-proBNP的“三分界点”策略评估HF的可能性。主要结局是30天全因院内死亡。使用最小绝对收缩和选择算子(LASSO)和多因素逻辑回归分析预后危险因素,进一步制定列线图以预测死亡率。在30天的随访期内,402例患者中有27.4%死亡。HF可能性大的患者死亡率显著高于灰色区域患者和HF可能性小的患者(分别为40.8% vs. 25%和16.5%,P<0.001)。HF可能性大[比值比(OR)1.97,95%置信区间(CI)1.13 - 3.42]、年龄(OR 1.04,95% CI 1.02 - 1.06)、淋巴细胞(OR )